OBJECTIVES: To identify predictors of clinical improvement and intubation/death in tocilizumab-treated severe COVID19, focusing on IL6 and CRP longitudinal monitoring. METHODS: 173 consecutive patients with severe COVID-19 pneumonia receiving tocilizumab in Reggio Emilia province Hospitals between 11 March and 3 June 2020 were enrolled in a prospective cohort study. Clinical improvement was defined as status improvement on a six-category ordinal scale or discharge from the hospital, whichever came first. A composite outcome of intubation/death was also evaluated. CRP and IL-6 levels were determined before TCZ administration (T0) and after 3 (T3), and 7 (T7) days. RESULTS: At multivariate analysis T0 and T3 CRP levels were negatively associated with clinical improvement (OR 0.13, CI 0.03-0.55 and OR 0.11, CI 0.0-0.46) (p=0.006 and p=0.003) and positively associated with intubation/death (OR 17.66, CI 2.47-126.14 and OR 5.34, CI: 1.49-19.12) (p=0.01 and p=0.004). No significant associations with IL-6 values were observed. General linear model analyses for repeated measures showed significantly different trends for CRP from day 3 to day 7 between patients who improved and those who did not, and between patients who were intubated or died and those who were not (p<0.0001 for both). ROC analysis identified a baseline CRP level of 15.8 mg/dl as the best cut-off to predict intubation/death (AUC = 0.711, sensitivity = 0.67, specificity = 0.71). CONCLUSIONS: CRP serial measurements in the first week of TCZ therapy are useful in identifying patients developing poor outcomes.

Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia / Cassone, G.; Dolci, G.; Besutti, G.; Muratore, F.; Bajocchi, G.; Mancuso, P.; Catanoso, M.; Spaggiari, L.; Galli, E.; Palermo, A.; Pipitone, N.; Croci, S.; Massari, M.; Facciolongo, N.; Menzella, F.; Negri, E. A.; Zerbini, A.; Belloni, L.; Cimino, L.; Teopompi, E.; Sampaolesi, F.; Salsi, P.; Costantini, M.; Giorgi Rossi, P.; Aldigeri, R.; Salvarani, C.. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - 38:6(2020), pp. 1215-1222.

Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia

Cassone G.;Dolci G.;Besutti G.;Spaggiari L.;Galli E.;Palermo A.;Menzella F.;Cimino L.;Salvarani C.
2020-01-01

Abstract

OBJECTIVES: To identify predictors of clinical improvement and intubation/death in tocilizumab-treated severe COVID19, focusing on IL6 and CRP longitudinal monitoring. METHODS: 173 consecutive patients with severe COVID-19 pneumonia receiving tocilizumab in Reggio Emilia province Hospitals between 11 March and 3 June 2020 were enrolled in a prospective cohort study. Clinical improvement was defined as status improvement on a six-category ordinal scale or discharge from the hospital, whichever came first. A composite outcome of intubation/death was also evaluated. CRP and IL-6 levels were determined before TCZ administration (T0) and after 3 (T3), and 7 (T7) days. RESULTS: At multivariate analysis T0 and T3 CRP levels were negatively associated with clinical improvement (OR 0.13, CI 0.03-0.55 and OR 0.11, CI 0.0-0.46) (p=0.006 and p=0.003) and positively associated with intubation/death (OR 17.66, CI 2.47-126.14 and OR 5.34, CI: 1.49-19.12) (p=0.01 and p=0.004). No significant associations with IL-6 values were observed. General linear model analyses for repeated measures showed significantly different trends for CRP from day 3 to day 7 between patients who improved and those who did not, and between patients who were intubated or died and those who were not (p<0.0001 for both). ROC analysis identified a baseline CRP level of 15.8 mg/dl as the best cut-off to predict intubation/death (AUC = 0.711, sensitivity = 0.67, specificity = 0.71). CONCLUSIONS: CRP serial measurements in the first week of TCZ therapy are useful in identifying patients developing poor outcomes.
38
6
1215
1222
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia / Cassone, G.; Dolci, G.; Besutti, G.; Muratore, F.; Bajocchi, G.; Mancuso, P.; Catanoso, M.; Spaggiari, L.; Galli, E.; Palermo, A.; Pipitone, N.; Croci, S.; Massari, M.; Facciolongo, N.; Menzella, F.; Negri, E. A.; Zerbini, A.; Belloni, L.; Cimino, L.; Teopompi, E.; Sampaolesi, F.; Salsi, P.; Costantini, M.; Giorgi Rossi, P.; Aldigeri, R.; Salvarani, C.. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - 38:6(2020), pp. 1215-1222.
Cassone, G.; Dolci, G.; Besutti, G.; Muratore, F.; Bajocchi, G.; Mancuso, P.; Catanoso, M.; Spaggiari, L.; Galli, E.; Palermo, A.; Pipitone, N.; Croci, S.; Massari, M.; Facciolongo, N.; Menzella, F.; Negri, E. A.; Zerbini, A.; Belloni, L.; Cimino, L.; Teopompi, E.; Sampaolesi, F.; Salsi, P.; Costantini, M.; Giorgi Rossi, P.; Aldigeri, R.; Salvarani, C.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1238663
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact